Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
Colon cancer is the second leading cause of cancer death in the UnitedStates. The probability of cure is directly related to the stage of thecancer at diagnosis and surgical resection. Identifying patients with thisdisease who have been shown to benefit from therapy is difficult at thepresent time due to the lack of reliable biomarkers. The purpose of thisstudy was to identify proteins in tissue samples from patients with coloncancer that might be reliable biomarkers for this disease. To this end,pressure cycling technology (PCT) was used to extract the proteins from thevarious tissue samples that were studied.
Dr. Alexander Lazarev, Vice President of Research and Development ofPressure BioSciences, said: "The data presented by Dr. Momeni and hercolleagues indicate that an apparent tumor signature protein (hCG1787564)extracted from colon tumor tissue by PCT might be a biomarker that could be ofbenefit to surgeons treating colon cancer patients. It is gratifying that PCTis beginning to be used by independent scientists in the preparation of theirsamples for important scientific studies, such as in the case of colon cancerresearch."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused onthe development of a novel, enabling technology called Pressure CyclingTechnology (PCT). PCT uses cycles of hydrostatic pressure between ambient andultra-high levels (up to 35,000 psi and greater) to control bio-molecularinteractions. PBI currently holds 13 US and 6 foreign patents coveringmultiple applications of PCT in the life sciences field, including such areasas genomic and proteomic sample preparation, pathogen inactivation, thecontrol of enzymes, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company'sintentions, hopes, beliefs, expectations, or predictions of the future are"forward-looking'' statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements include the use of the PCT SPSby the Brooklyn Hospital Center and the NYU School of Medicine, the results oftheir studies having been presented at the Annual Scientific Meeting of theAmerican College of Gastroenterology. These statements are based upon theCompany's current expectations, forecasts, and assumptions that are subject torisks, uncertainties, and other factors that could cause actual outcomes andresults to differ materially from those indicated by these forward-lookingstatements. These risks, uncertainties, and other factors include, but arenot limited to: unforeseen technological difficulties that the Company mayencounter in the development of the PCT technology and the PCT SamplePreparation System; the possibility that other laboratories may be unable toduplicate the results generated by Dr. Momeni and her colleagues; thepossibility that the data generated may not be beneficial in the developmentof new therapeutics and diagnostics for colon cancer; that due to competitiveproducts, services, and technological advances, PCT may not be the preferredmethod of sample preparation by other scientists and laboratories; and theother risks and uncer
You May Also Like